CA-RECVUE
14.1.2021 15:02:34 CET | Business Wire | Press release
RecVue, provider of Order Lifecycle Management (OLM) solutions designed to modernize the complex order-to-cash (O2C) processes for enterprises, has raised $13 million in a Series A round. Cota Capital led the round, in which Epic Ventures and Long Light Capital also participated. RecVue will use the funding to expand its engineering, go-to-market efforts and international presence.
“We offer the industry’s only suite of OLM solutions that are purpose-built to address the growing gap between front- and back-office business processes,” said Nishant Nair, founder and CEO of RecVue. “This fundraising round provides a dynamic foundation for rapid growth in our go-to-market operations as well as allowing us to quickly add new capabilities to our OLM suite of applications to scale to the $150 billion revenue under management target.”
Bobby Yazdani, managing partner for Cota Capital, added “Since its launch, RecVue’s technology has been transforming the order-to-cash process, helping customers innovate and operate new business models and manage complex revenue streams at unprecedented scale, speed and efficiency. The RecVue leadership team has crafted a powerful strategic plan that has them poised to transform order-to-cash needs of hundreds of large enterprises and process billions of transactions over the next several years.”
The “middle office” is the command center for the enterprise, encompassing all the business functions that sit between the traditional front-and-back systems -- from initial engagement to managing relationships and complex order-to-cash processes such as billing, revenue management and channel partner compensation. The middle office presents a largely untapped opportunity to harness revenue potential by leveraging back-office data to influence front-office business decisions.
Yet, many organizations today are experiencing a growing “middle office” gap between their customer-facing front-office CRM systems and transaction-heavy, back-office ERP systems. Faced with data silos, fragmented and often manual processes, and custom-built applications and spreadsheets, many companies are forced to do complicated data integrations to make CRM and ERP systems work together.
RecVue addresses the middle office gap more efficiently and effectively by fully automating the complex order-to-cash processes for billing, revenue, accruals management and channel partner payments. Additionally, RecVue provides robust analytics and reporting. Customers using RecVue’s unified approach have benefited by closing their books earlier, reducing their compliance risk, and significantly lowering their total cost and overhead.
“We’ve been able to significantly reduce the cost and complexity of our revenue operations using RecVue’s OLM suite of applications,” said Philipp Lustenberger, CFO, General Assembly, part of Adecco group. “Automating, streamlining, and optimizing our order-to-cash process has helped our finance and operations teams focus more on the strategic challenges that we face.”
Mark Thomason, IDC’s Research Director for Digital Business Models and Monetization said, “The COVID-19 pandemic has accelerated the trend toward recurring business models and selling over new digital channels, including multi-partner marketplaces. This has increased monetization complexity and the need to scale quickly. Future-focused companies are adopting agile monetization systems such as RecVue’s OLM suite to easily implement complex recurring business models, automate the order-to-cash process, and easily manage partner settlement to enable the goal of continuous accounting close.”
About RecVue
RecVue empowers enterprises to modernize their billing and revenue operations at speed and scale by harnessing previously untapped revenue potential and leveraging front-office CRM data and back-office ERP systems to influence business decisions. Trusted by the world’s leading companies in business services, transportation and logistics, financial services, media and technology, including Hertz, General Assembly, ACI Worldwide, and Textainer, RecVue’s suite of purpose-built cloud applications enable enterprises to expand recurring revenue and automate complex order-to-cash (O2C) processes. For more information, visit www.recvue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom